ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies. It has several subsidiaries in North America and Europe including entities, such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the IPA Family). Its Contract Research Organizations (CRO) services include B cell Select; Phage Display; DeepDisplay; Abthena Bispecifics; LucinaTech Humanization; Affinity Maturation; Immunization, hybridoma, sequencing; rPEx protein manufacturing, and Cell line development. The Company utilizes custom antigen modeling, target analysis using Natural Language Processing and the HYFTTM analysis to lay the groundwork for the subsequent experimental phases.
Símbolo de cotizaciónIPA
Nombre de la empresaImmunoprecise Antibodies Ltd
Fecha de salida a bolsaJan 30, 1987
Director ejecutivoDr. Jennifer Lynne Bath, Ph.D.
Número de empleados- -
Tipo de seguridadOrdinary Share
Fin del año fiscalJan 30
DirecciónIndustrious 823 Congress Ave Suite 300
CiudadAUSTIN
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal78701
Teléfono16048060626
Sitio Webhttps://www.ipatherapeutics.com/
Símbolo de cotizaciónIPA
Fecha de salida a bolsaJan 30, 1987
Director ejecutivoDr. Jennifer Lynne Bath, Ph.D.
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos